$0.77
5.06% yesterday
Nasdaq, Jun 27, 10:02 pm CET
ISIN
US1850631045
Symbol
CLSD
Sector
Industry

Clearside Biomedical, Inc. Stock price

$0.77
-0.05 6.06% 1M
-0.18 18.95% 6M
-0.18 18.95% YTD
-0.51 39.84% 1Y
-0.83 51.88% 3Y
-1.16 60.10% 5Y
-6.48 89.38% 10Y
-6.48 89.38% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.04 5.06%
ISIN
US1850631045
Symbol
CLSD
Sector
Industry

Key metrics

Basic
Market capitalization
$59.8m
Enterprise Value
$46.2m
Net debt
$-13.6m
Cash
$13.6m
Shares outstanding
77.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
15.91 | 22.40
EV/Sales
12.29 | 17.30
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-154.64%
Return on Equity
88.41%
ROCE
-176.52%
ROIC
-776.91%
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
$3.8m | $2.7m
EBITDA
$-25.6m | $-33.6m
EBIT
$-25.9m
Net Income
$-30.8m | $-32.9m
Free Cash Flow
$-23.6m
Growth (TTM | estimate)
Revenue
-55.56% | 60.90%
EBITDA
-0.87% | -17.27%
EBIT
-1.67%
Net Income
11.92% | 4.28%
Free Cash Flow
-15.28%
Margin (TTM | estimate)
Gross
89.45%
EBITDA
-679.99% | -1,258.33%
EBIT
-687.51%
Net
-818.57% | -1,230.89%
Free Cash Flow
-627.15%
More
EPS
$-0.41
FCF per Share
$-0.31
Short interest
0.46%
Employees
32.00
Rev per Employee
$50.00k
Show more

Is Clearside Biomedical, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Clearside Biomedical, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Clearside Biomedical, Inc. forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Clearside Biomedical, Inc. forecast:

Buy
92%
Hold
8%

Financial data from Clearside Biomedical, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3.76 3.76
56% 56%
100%
- Direct Costs 0.40 0.40
-
11%
3.37 3.37
-
90%
- Selling and Administrative Expenses 12 12
2% 2%
314%
- Research and Development Expense 17 17
21% 21%
464%
-26 -26
1% 1%
-681%
- Depreciation and Amortization 0.28 0.28
250% 250%
7%
EBIT (Operating Income) EBIT -26 -26
2% 2%
-688%
Net Profit -31 -31
12% 12%
-819%

In millions USD.

Don't miss a Thing! We will send you all news about Clearside Biomedical, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Clearside Biomedical, Inc. Stock News

Neutral
GlobeNewsWire
11 days ago
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the  Long-Lasting Benefits of a Tyrosine Kinase Inhibitor - ALPHARETTA, Ga., June 17, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of ...
Neutral
GlobeNewsWire
about one month ago
ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in a fireside chat at the Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May 27, 2025, at 9:00 a.m.
Neutral
GlobeNewsWire
about one month ago
- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexible Maintenance Dosing - - Multiple Milestones Achieved by Commercial and Development Partners - - Use of Suprachoroidal Drug Delivery Featured in Over 15 Presentations at Major Ophthalmic Medical Me...
More Clearside Biomedical, Inc. News

Company Profile

Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Head office United States
CEO George Lasezkay
Employees 32
Founded 2011
Website clearsidebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today